WuXi Biologics provides customized antibody discovery platforms for monoclonal antibodies (mAbs), bispecific antibodies (bsAbs), multispecific antibodies (msAbs), and immunocytokines. Their services aim to accelerate biology-driven lead identification by offering tailored solutions. This includes expertise in various therapeutic modalities, ensuring clients can efficiently identify and optimize lead candidates for biologics development.
Strengthening antibody discovery capabilities is critical for WuXi Biologics' role as a CRDMO. By offering advanced, customized platforms, the company can attract more early-stage drug discovery projects, securing a pipeline of future development and manufacturing opportunities. This focus on lead identification and optimization directly impacts the success rate of drug development, enhancing WuXi Biologics' value proposition to clients and its competitive standing.
Customized antibody discovery platforms.
Supports mAbs, bsAbs, msAbs, and immunocytokines.
Aims to accelerate biology-driven lead identification.
WuXi Biologics' global operations support clients worldwide in their antibody discovery efforts, contributing to the advancement of biopharmaceutical research across different regions.
Supports mAbs, bsAbs, msAbs, and immunocytokines.
Aims to accelerate biology-driven lead identification.
Sign in to save notes on signals.
Sign In